- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04705389
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines (SUMMERTIME)
May 17, 2021 updated by: University Hospital, Tours
Merkel cell carcinoma (MCC) is a rare aggressive skin carcinoma.
Approximately 80% of MCC are related to the Merkel Cell Polyomavirus (MCPyV).
Although rates of relapse are high, the follow-up strategy lacks consensus.
Patients are usually assessed clinically every 3 to 6 months for the first 2-3 years, and every 6 to 12 months thereafter.
In the European guidelines, patients with early stages are monitored with clinical examination and ultrasonography of lymph nodes, while whole-body imaging is optional in patients with stage III disease, on a yearly basis for 5 years.
Such strategy may prevent the diagnosis of infra-clinical recurrences, whereas patients could still be treated with surgery or radiation therapy.
Until 2017, patients with advanced disease were treated with chemotherapies, with no long-term benefit.
Immunotherapies with PD-1/PD-L1 inhibitors currently allow durable responses in 50% of such patients.
This major change in the management of MCC patients argues for a follow-up strategy that would allow early diagnosis of infra-clinical metastases, when tumoral burden is still low.
Given that all patients cannot be monitored by systematic regular imaging, additional non-invasive tools are needed.
Blood-based biomarkers as a surrogate of tumor burden are advantageous as they can be repeated over time, providing guidance on when imaging is necessary.
The study aims to assess two blood biomarkers, MCPyV T-Ag antibodies and cell-free miR-375, in a prospective fashion from baseline diagnosis, in a cohort of 150 European MCC patients
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mahtab SAMIMI, MD-PhD
- Phone Number: +33 02.47.47.46.25
- Email: mahtab.samimi@univ-tours.fr
Study Locations
-
-
-
Vienna, Austria
- Department of Dermatology, Medical University of Vienna
-
Contact:
- Robert Loewe, MD
- Email: robert.loewe@meduniwien.ac.at
-
Principal Investigator:
- Robert Loewe
-
-
-
-
-
Helsinki, Finland, 00100
- University Hospital of Helsinki, Finland
-
Contact:
- Helka Sahi, MD PhD
- Email: helka.sahi@hus.fi
-
Principal Investigator:
- Helka Sahi
-
-
-
-
-
Tours, France, 37044
- Dermatology Dept, Hospital University of Tours
-
Contact:
- Mahtab SAMIMI, MD-PhD
- Email: mahtab.samimi@univ-tours.fr
-
Principal Investigator:
- Mahtab SAMIMI, MD-PhD
-
-
-
-
-
Essen, Germany, 45141
- Translational Skin Cancer Research
-
Contact:
- Jurgen Becker, MD PhD
- Email: j.becker@dkfz-heidelberg.de
-
Principal Investigator:
- Jurgen Becker
-
-
-
-
-
Naples, Italy, 80131
- National Tumour Institute "Fondazione G. Pascale" Unit of Melanoma - Cancer Immunotherapy and Innovative therapy
-
-
-
-
-
Maastricht, Netherlands
- Academic Hospital of Maastricht
-
Contact:
- Nicole KELLENERS-SMITH, MD PhD
- Email: n.kelleners.smeets@mumc.nl
-
Principal Investigator:
- Nicole KELLENERS-SMITH
-
-
-
-
-
Bucharest, Romania, 050474
- Department of Dermatology, Carol Davila University of Medicine and Pharmacy
-
Contact:
- Ana Maria Forsea, MD PhD
- Email: aforsea@yahoo.com
-
Principal Investigator:
- Ana Maria Forsea
-
-
-
-
-
Gothenburg, Sweden
- Skin Cancer and Surgery Center, Sahlgrenska University Hospital
-
Contact:
- John Paoli, MD PhD
- Email: john.paoli@vgregion.se
-
Principal Investigator:
- John Paoli
-
-
-
-
-
Ankara, Turkey
- Department of Dermatology, Başkent University Faculty of Medicine
-
Contact:
- Deniz SECKIN, MD
- Email: denizseckin50@gmail.com
-
Principal Investigator:
- Deniz SECKIN
-
-
-
-
-
Birmingham, United Kingdom
- Queen Elizabeth Hospital
-
Contact:
- Agustin Martin-Clavijo, MD
- Email: agustin.martin-clavijo@uhb.nhs.uk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a " de novo " diagnosis of MCC, confirmed on histological criteria (neuroendocrine morphology, CK20 staining and/or neuroendocrine and/or SATB2 staining, exclusion of differential diagnosis)
- ≥ 18 years of age
- Written informed consent obtained from the participant
Exclusion Criteria:
- Patients following any measures of legal presentation
- Pregnancy or breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Case group
Intervention only includes additional blood sampling at baseline and during follow up (5 samplings).
|
blood samples
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the diagnostic performances of two blood biomarkers (T-antigen antibodies and miR375) in detecting disease recurrence during follow up of patients with Merkel Cell Carcinoma
Time Frame: 12 months
|
Diagnostic performances (specificity, sensitivity, predictive values) of each biomarker will be assessed at the end of follow up, in relation with patients' outcomes (remission and recurrence).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess if these two blood biomarkers (T-antigen antibodies and miR375) assessed at baseline are associated with prognosis and response to treatments.
Time Frame: 12 months
|
Cox regression analysis will be performed to evaluate the clinical and biological factors associated with recurrence, death of disease, response to treatments.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Mahtab SAMIMI, MD-PhD, University Hospital, Tours
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Fan K, Ritter C, Nghiem P, Blom A, Verhaegen ME, Dlugosz A, Odum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC. Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. Clin Cancer Res. 2018 Dec 1;24(23):5873-5882. doi: 10.1158/1078-0432.CCR-18-1184. Epub 2018 Jul 30.
- Kervarrec T, Tallet A, Miquelestorena-Standley E, Houben R, Schrama D, Gambichler T, Berthon P, Le Corre Y, Hainaut-Wierzbicka E, Aubin F, Bens G, Tabareau-Delalande F, Beneton N, Fromont G, Arbion F, Leteurtre E, Touze A, Samimi M, Guyetant S. Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas. Mod Pathol. 2019 Apr;32(4):499-510. doi: 10.1038/s41379-018-0155-y. Epub 2018 Oct 22.
- Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A, Iyer J, Moshiri AS, Tarabadkar ES, Carter JJ, Bhatia S, Kawasumi M, Galloway DA, Wener MH, Nghiem P. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer. 2017 Apr 15;123(8):1464-1474. doi: 10.1002/cncr.30475. Epub 2016 Dec 7.
- Samimi M, Molet L, Fleury M, Laude H, Carlotti A, Gardair C, Baudin M, Gouguet L, Maubec E, Avenel-Audran M, Esteve E, Wierzbicka-Hainaut E, Beneton N, Aubin F, Rozenberg F, Dupin N, Avril MF, Lorette G, Guyetant S, Coursaget P, Touze A. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol. 2016 Apr;174(4):813-22. doi: 10.1111/bjd.14313. Epub 2016 Feb 3.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 1, 2021
Primary Completion (ANTICIPATED)
September 1, 2021
Study Completion (ANTICIPATED)
September 1, 2023
Study Registration Dates
First Submitted
January 8, 2021
First Submitted That Met QC Criteria
January 8, 2021
First Posted (ACTUAL)
January 12, 2021
Study Record Updates
Last Update Posted (ACTUAL)
May 18, 2021
Last Update Submitted That Met QC Criteria
May 17, 2021
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- DNA Virus Infections
- Tumor Virus Infections
- Neuroendocrine Tumors
- Polyomavirus Infections
- Carcinoma, Neuroendocrine
- Carcinoma
- Carcinoma, Merkel Cell
Other Study ID Numbers
- DR200079
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Merkel Cell Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Merkel Cell Carcinoma | Metastatic Merkel Cell Carcinoma | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Cutaneous Merkel... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Merkel Cell Carcinoma | Refractory Merkel Cell Carcinoma | Locally Advanced Merkel Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)CompletedRecurrent Merkel Cell Carcinoma | Stage III Merkel Cell Carcinoma AJCC v7 | Stage IV Merkel Cell Carcinoma AJCC v7 | Stage IIIA Merkel Cell Carcinoma AJCC v7 | Stage IIIB Merkel Cell Carcinoma AJCC v7United States
-
Melanoma and Skin Cancer Trials LimitedRecruitingNeuroendocrine Tumors | Merkel Cell Carcinoma | Merkel Cell Carcinoma, Stage I | Merkel Cell Carcinoma, Stage II | Merkel Cell Carcinoma, Stage III | Carcinoma Neuroendocrine SkinAustralia, New Zealand
-
University of WashingtonEMD SeronoActive, not recruitingStage III Merkel Cell Carcinoma AJCC v8 | Stage IIIB Merkel Cell Carcinoma AJCC v8 | Stage IIIA Merkel Cell Carcinoma AJCC v8United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
National Cancer Institute (NCI)SuspendedPathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
University of WashingtonIncyte CorporationRecruitingMerkel Cell Carcinoma | Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8United States
-
ImmunityBio, Inc.UnknownStage IIIB Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoTerminatedStage IV Merkel Cell Carcinoma AJCC v7 | Merkel Cell Polyomavirus InfectionUnited States
Clinical Trials on Samples
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Centre Georges Francois LeclercCompleted
-
Centre Hospitalier Universitaire de NīmesCompletedHenoch Schönlein PurpuraFrance
-
Centre Hospitalier Universitaire DijonCompletedPrimary Immune Thrombocytopenia (ITP)France
-
Institut BergoniéUnknown
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPaediatric MalignanciesFrance
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
University Hospital, BordeauxRecruitingSystemic Sclerosis | SclerodermaFrance
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Innovaderm Research Inc.RecruitingPlaque Psoriasis | Atopic Dermatitis | Hidradenitis Suppurativa | Palmoplantar Pustulosis | Acne | Chronic Hand EczemaCanada